Aria Vaishnavi
Department of Genetics, Division of Discovery Science
Education & Training
Degree-Granting Education
| 2017 | University of Colorado Denver Anschutz, Aurora, CO, USA, PHD, Cancer Biology |
| 2007 | Washington State University, Pullman, WA, USA, BS, Biochemistry and Molecular Biology |
Postgraduate Training
| 2017-2022 | Postdoctoral Fellow, University of Utah Huntsman Cancer Institute, Salt Lake City, UT |
Honors & Awards
| 2022 | Cancer Prevention Research Institute of Texas (CPRIT) Scholar of Cancer Research |
| 2022 | University of Texas Rising Science Technology Acquisition and Retention Recipient (STARs) |
| 2021 | Lung Cancer Research Foundation Pilot Award |
| 2020 | National Cancer Institute Pathway to Independence Early K99 Fellowship Award Recipient |
| 2020 | AACR Scholar-in-Training Award |
| 2019 | NIGMS Scholarship CSHL Single Cell Analysis Course |
| 2018 | National Cancer Institute National Research Service Award F32 recipient |
| 2017 | Huntsman Cancer Institute Susan Cooper Jones Endowed Fellowship in Cancer Biology |
Selected Publications
Peer-Reviewed Articles
- Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner EE, Scherzer MT, Schuman S, Van Veen JE, Murphy B, Hackett CS, Dupuy AJ, Chmura SA, van der Weyden L, Newberg JY, Liu A, Mann K, Rust AG, Weiss WA, Kinsey CG, Adams DJ, Grossmann A, Mann MB, McMahon M. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Res 82(22):4261-4273, 2022. PMID: 36112789.
- Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep 32(5):107994, 2020. PMID: 32755586.
- Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 77(13):3551-3563, 2017. e-Pub 2017. PMID: 28428274.
- Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov 5(10):1049-57, 2015. e-Pub 2015. PMID: 26216294.
- Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med 21(9):1038-47, 2015. e-Pub 2015. PMID: 26301689.
- Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5(1):25-34, 2015. e-Pub 2014. PMID: 25527197.
- Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19(11):1469-1472, 2013. e-Pub 2013. PMID: 24162815.
- Fox RM, Vaishnavi A, Maruyama R, Andrew DJ. Organ-specific gene expression: the bHLH protein Sage provides tissue specificity to Drosophila FoxA. Development 140(10):2160-71, 2013. e-Pub 2013. PMID: 23578928.
- Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One 8(12):e82236, 2013. e-Pub 2013. PMID: 24349229.
Grant & Contract Support
| Title: | The urgent need for translational studies of BRAF mutations beyond V600E |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Title: | Elucidating the Molecular Mechanisms of Radon-Induced Lung Cancer through a Novel Mouse Model |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | Principal Investigator |
| Title: | Vaishnavi_Equipment |
| Funding Source: | University of Texas STARS |
| Role: | Principal Investigator |
| Title: | Molecular Characterization of Radon-Induced Lung Cancer in Never-Smoker Patients and PDX models |
| Funding Source: | Huntsman Cancer Institute Lung DOT |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified August 15, 2023